
Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents
DESIGN: Retrospective review of the treatment records and laboratory tests of patients initiated on MDR-TB treatment (January–December 2014). The glomerular filtration rates (eGFR) estimated pre- and post-treatment were compared using the analysis of variance test. Renal insufficiency was defined as an eGFR of <60 ml/min/1.73 m2. Use of KM or TDF and association with renal insufficiency was assessed using Kaplan-Meier plots and Cox proportional hazards analysis.
RESULTS: The baseline mean eGFR for the three groups was similar (P = 0.24): 139.3 ± 25.6 ml/min for the KM group (n = 68), 131.1 ± 25.7 ml/min for the KM+TDF group (n = 44) and 134.2±34.4 ml/min for the KM+Other group (n = 23). After 8 months, the values had declined significantly to respectively 104.8 ± 37.5 ml/min (P < 0.001), 101.5 ± 38.3 ml/min (P < 0.001) and 111.5 ± 41.7 ml/min (P = 0.01). Co-treatment with KM+ART was associated with an increased risk of renal insufficiency (hazard ratio [HR] 1.8, 95%CI 0.7–4.1, P = 0.20 for KM+TDF, and HR 3.5, 95%CI 1.4–8.2, P = 0.005 for KM+Other ART).
CONCLUSION: Renal function declined at a similar rate in MDR-TB patients treated with KM-based regimens compared with patients treated concomitantly with TDF-based or other ART. The risk of renal insufficiency was greater for patients on ART.
Keywords: Namibia; TB-HIV co-infection; aminoglycosides; nephrotoxicity; nucleoside reverse transcriptase inhibitors
Document Type: Research Article
Affiliations: 1: Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands 2: National Tuberculosis and Leprosy Program, Ministry of Health and Social Services, Windhoek, Namibia 3: University of Namibia School of Pharmacy, Windhoek, Namibia 4: Operations Research and Program Monitoring, Directorate of Special Programmes, Ministry of Health and Social Services, Windhoek, Namibia; National HIV and STI Control Programme, Ministry of Health and Social Services, Windhoek, Namibia 5: National HIV and STI Control Programme, Ministry of Health and Social Services, Windhoek, Namibia 6: Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands
Publication date: December 1, 2017
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content